News & Updates
Showing Multidisciplinary articles
Showing
Diabetics with severe insulin resistance exhibit poor physical fitness
Individuals with severe insulin-resistant diabetes (SIRD) appear to have the lowest physical fitness compared with other diabetes subgroups despite similar endothelial function across all cohorts, a study has shown. Moreover, those with severe autoimmune diabetes (SAID) have the lowest cardiovascular risk within the first year following diagnosis relative to other clusters.
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.
T-DXd ups PFS vs T-DM1 in HER2-positive metastatic breast cancer
Trastuzumab deruxtecan (T-DXd) reduces the risk of disease progression or death by 72 percent vs trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer whose disease progressed during or after treatment with an anti–HER-2 antibody, the first interim analysis of the DESTINY-Breast03 trial has shown.
Exclusionary testing most efficient and cost-saving for NSCLC
Exclusionary testing, involving upfront testing for EGFR and ALK followed by next-generation sequencing (NGS) for other genomic alterations (GAs), is the most efficient and cost-saving molecular testing strategy for patients with metastatic non-small-cell lung cancer (NSCLC) in Hong Kong and perhaps East Asia, researchers from the Chinese University of Hong Kong (CUHK) have reported.